^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    FH-TCR-Tᴍsʟɴ

    i
    Other names: FH-TCR-Tᴍsʟɴ, Autologous Mesothelin-specific TCR-T Cells
    Associations

    News

    Trials
    Company:
    Fred Hutchinson Cancer Center
    Drug class:
    TCR modulator, Mesothelin inhibitor
    Related drugs:
    Associations

    News

    Trials
    18d
    Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, Fred Hutchinson Cancer Center | Recruiting --> Active, not recruiting | N=15 --> 9
    Enrollment closed • Enrollment change
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MSLN (Mesothelin)
    |
    MSLN expression • HLA-A*02
    |
    cyclophosphamide • bendamustine • fludarabine IV • FH-TCR-Tᴍsʟɴ
    4ms
    Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1, N=15, Recruiting, Fred Hutchinson Cancer Center | Trial primary completion date: Jun 2024 --> Dec 2024
    Trial primary completion date • Metastases
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MSLN (Mesothelin)
    |
    cyclophosphamide • bendamustine • fludarabine IV • FH-TCR-Tᴍsʟɴ
    10ms
    Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1, N=15, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Sep 2024 --> Jun 2025 | Trial primary completion date: Dec 2023 --> Jun 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MSLN (Mesothelin)
    |
    MSLN expression • HLA-A*02
    |
    cyclophosphamide • bendamustine • fludarabine IV • FH-TCR-Tᴍsʟɴ